Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0JHZDI
ADC Name	Trastuzumab-G-13
Synonyms	Trastuzumab G-13 Click to Show/Hide
Organization	Pierre Fabre SA.
Drug Status	Investigative
Indication	In total 2 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Lung cancer [ICD11:2C25] Investigative
Drug-to-Antibody Ratio	4
	3D MOL	2D MOL
Antibody Name	Trastuzumab		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Undisclosed
Linker Name	Trastuzumab-G-13 linker
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 82.41	%	CVCL_2077	Breast ductal carcinoma
Tumor Growth Inhibition value (TGI)	≈ 100	%	CVCL_0609	Lung adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 82.41% (Day 34)	Moderate HER2 expression (HER2++)
Method Description	Six days after JIMT-3 cell implantation, when tumors reached an average size of 220-230 mm³, the animals were divided into groups of 6 mice according to tumor sizeand aspect. All compounds were injected intraperitoneally (i.p.). In this example, the anti-tumor activity of Tratuzumab mAb coupled with G-13 at about DAR 4 was evaluated after 1 injections of a 3 mg/kg dose at D6. Click to Show/Hide
In Vivo Model	JIMT-1 CDX model
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 41)	Positive HER2 expression (HER2+++/++)
Method Description	Six days after Calu-3 cell implantation, when tumors reached an average size of 250-260 mm³, the animals were divided into groups of 6 mice according to tumor sizeand aspect. All compounds were injected intraperitoneally (i.p.). In this example, the anti-tumor activity of Tratuzumab mAb coupled with G-13 at about DAR 4 was evaluated after 1 injections of a 3 mg/kg dose at D6. Click to Show/Hide
In Vivo Model	Calu-3 CDX model
In Vitro Model	Lung adenocarcinoma	Calu-3 cells		CVCL_0609

References

Ref 1	Antibody-drug-conjugate and its use for the treatment of cancer.